Experts recommended Johnson & Johnson’s COVID-19 vaccine for use

Experts recommended Johnson & Johnson's COVID-19 vaccine for use

The advisory panel of experts to the health regulator FDA has recommended Johnson & Johnson’s COVID-19 vaccine for use in the United States, according to the panel’s vote.
The FDA is expected to approve the vaccine for use on “emergency” grounds as early as Saturday. In that case, three coronavirus vaccines will already be used in the U.S., the other two being made by Pfizer and Moderna.
Experts on the advisory board unanimously ruled that the potential benefits of the vaccine outweigh the possible risks.
The vaccine is produced by Janssen Pharmaceutica, a division of Johnson & Johnson. Unlike vaccines already approved in the U.S., this vaccine is a vector vaccine, similar to Russia’s Sputnik V and the Anglo-Swedish AstraZeneca. The vaccine uses the cold virus and affects the spike protein on the surface of the virus. Unlike other U.S.-approved vaccines, this one requires only one injection rather than two.
Johnson & Johnson plans to deliver up to 20 million doses of the vaccine by the end of March and up to 100 million doses by the end of June.